IP Library Granted Patent US 7,709,490
Granted Patent B2
US 7,709,490 · App. 12/267,912 · Granted May 4, 2010

4,5-diphenyl-pyrimidinyl substituted carboxylic acids, method for the production and use thereof as medicaments

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,709,490
App. No.
12/267,912
Granted
May 4, 2010
Kind
B2
Abstract

This invention relates to a compound of formula I, wherein R1, R2, m, n and X are as defined herein, or a physiologically tolerated salt thereof, its pharmaceutical composition and use for lowering blood glucose, treating diabetes, or increasing insulin release.

Claims (26)

1. A compound of formula I,

wherein:

R1 and R2 are independently of one another (C 1 -C 6 )-alkyl O—(C 1 -C 6 )-alkyl, NH 2 , NH(C 1 -C 4 )-alkyl, N[(C 1 -C 4 )-alkyl] 2 , OH, CN, F, Cl, Br, O-phenyl, CF 3 , OCF 3 or OCH 3 , wherein the alkyl moiety is optionally substituted one or more times by F, Cl, Br or CN;

n is 0, 1, 2, 3, 4 or 5;

m is 0, 1, 2, 3, 4 or 5;

X is (C 2 -C 10 )-alkynylene, which is optionally substituted one or more times by R3; and

R3 is NH 2 , NH(C 1 -C 4 )-alkyl, N[(C 1 -C 4 )-alkyl] 2 , F, Cl, Br, CN, OH, O—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl or (C 2 -C 6 )-alkynyl, wherein the alkyl, alkenyl and alkynyl moieties are optionally substituted one or more times by F, Cl, Br or CN;

or a physiologically tolerated salt thereof.

2. The compound according to claim 1 , wherein:

X is (C 4 -C 10 )-alkynylene, which is optionally substituted one or more times by R3; and

R3 is F, Cl, Br, CN, OH, O—(C 1 -C 6 )-alkyl, (C 1 -C 6 -alkyl, (C 2 -C 6 )-alkenyl or (C 2 -C 6 )-alkynyl, wherein the alkyl, alkenyl and alkynyl moieties are optionally substituted one or more times by F, Cl, Br or CN;

or a physiologically tolerated salt thereof.

3. The compound according to claim 1 , wherein:

n is 0, 1, 2;

m is 0, 1, 2; and

X is (C 4 -C 10 )-alkynylene;

or a physiologically tolerated salt thereof.

4. A pharmaceutical composition comprising the compound according to claim 1 or a physiologically tolerated salt thereof, in combination with a pharmaceutically acceptable excipient.

5. A pharmaceutical composition comprising the compound according to claim 2 or a physiologically tolerated salt thereof, in combination with a pharmaceutically acceptable excipient.

6. A pharmaceutical composition comprising the compound according to claim 3 or a physiologically tolerated salt thereof, in combination with a pharmaceutically acceptable excipient.

7. A method for lowering blood glucose, treating diabetes, or increasing insulin release, in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the compound according to claim 1 , or a physiologically tolerated salt thereof.

8. A method for lowering blood glucose, treating diabetes, or increasing insulin release, in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the compound according to claim 2 , or a physiologically tolerated salt thereof.

9. A method for lowering blood glucose, treating diabetes, or increasing insulin release, in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the compound according to claim 3 , or a physiologically tolerated salt thereof.

10. A process for manufacturing a pharmaceutical composition comprising the compound according to claim 1 or a physiologically tolerated salt thereof, in combination with a pharmaceutically acceptable excipient, which comprises mixing the compound according to claim 1 or the physiologically tolerated salt thereof, with the pharmaceutically acceptable excipient, and converting this mixture into a form suitable for administration.

11. A process for manufacturing a pharmaceutical composition comprising the compound according to claim 2 or a physiologically tolerated salt thereof, in combination with a pharmaceutically acceptable excipient, which comprises mixing the compound according to claim 2 or the physiologically tolerated salt thereof, with the pharmaceutically acceptable excipient, and converting this mixture into a form suitable for administration.

12. A process for manufacturing a pharmaceutical composition comprising the compound according to claim 3 or a physiologically tolerated salt thereof, in combination with a pharmaceutically acceptable excipient, which comprises mixing the compound according to claim 3 or the physiologically tolerated salt thereof, with the pharmaceutically acceptable excipient, and converting this mixture into a form suitable for administration.

Assignments (2)
CHANGE OF NAME Recorded Jun 20, 2012
From: SANOFI-AVENTIS
To: SANOFI
Reel/Frame 028413/0927 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2009
From: DEFOSSA, ELISABETH; GOERLITZER, JOCHEN; KLABUNDE, THOMAS; DIETRICH, VIKTORIA; STENGELIN, SIEGFRIED; HASCHKE, GUIDO; HERLING, ANDREAS; BARTOSCHEK, STEFAN
To: SANOFI-AVENTIS
Reel/Frame 022310/0257 →